ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer - Takeaways - MDSpire

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

Share

  • 1

    Dr. Julia Rotow reported on a study of silevertinib for EGFR non-small cell lung cancer variants.

  • 2

    Silevertinib may provide a new first-line treatment option for hard-to-treat lung cancer variants.

  • 3

    The study indicated encouraging brain activity associated with silevertinib.

  • 4

    Silevertinib was noted to have manageable side effects in the study.

  • 5

    The findings were presented at the ASCO26 conference.

Original Source(s)

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

  • July 1, 2026

Related Content

From voice biomarkers to telemedicine screening: developing and evaluating a voice-based AI model for laryngeal lesion detection using the Bridge2AI-Voice dataset

STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer

What starts at UCI Health can help shape the national conversation.

  • June 30, 2026

  • 1 min
Breast Cancer Incidence in Asian American, Native Hawaiian, and Pacific Islander Populations